Armed with readouts from the PURPOSE 1 and 2 trials, Gilead Sciences is now gearing up for global regulatory submissions for ...

Gilead Sciences’ shares closed up 2.7% at $83.16 yesterday, after it releases positive results of an interim analysis from a ...

An injected antiviral medicine, taken twice a year, appears to offer at-risk people near-complete protection against HIV ...

If approved, lenacapavir would be the first and only twice-yearly HIV prevention choice for people who need or want PrEP.

A drug currently used to treat HIV has also been found to dramatically reduce the risk of infection, significantly more than the primary option available for pre-exposure prophylaxis ...

Patients with HIV treated with antiretroviral therapy (ART) have a 31.5% chance of being anemic with many significantly ...

Long-term daily oral pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide was safe and highly effective for HIV prevention in adult cisgender men and transgender women who have sex ...